0000899243-21-036399.txt : 20210917
0000899243-21-036399.hdr.sgml : 20210917
20210917133841
ACCESSION NUMBER: 0000899243-21-036399
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210915
FILED AS OF DATE: 20210917
DATE AS OF CHANGE: 20210917
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Pfeffer Cary
CENTRAL INDEX KEY: 0001591092
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37998
FILM NUMBER: 211259858
MAIL ADDRESS:
STREET 1: C/O ELEVEN BIOTHERAPEUTICS
STREET 2: 215 FIRST STREET, SUITE 400
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Jounce Therapeutics, Inc.
CENTRAL INDEX KEY: 0001640455
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 454870634
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 780 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-259-3840
MAIL ADDRESS:
STREET 1: 780 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-09-15
0
0001640455
Jounce Therapeutics, Inc.
JNCE
0001591092
Pfeffer Cary
C/O THIRD ROCK VENTURES, LLC,
29 NEWBURY STREET, 3RD FLOOR
BOSTON
MA
02116
1
0
0
0
Common Stock
2021-09-15
4
J
0
0
D
0
I
See footnote
Common Stock
0
I
See footnote
Common Stock
50468
D
Pursuant to a 10b5-1 trading plan adopted on November 18, 2020 by Third Rock Ventures II, L.P. ("TRV II"), TRV II distributed for no consideration, 1,750,000 shares of Common Stock of the Issuer (the "Shares") on September 15, 2021, to its limited partners and to Third Rock Ventures GP II, L.P. ("TRV GP II"), the general partner of TRV II, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP II distributed, for no consideration, the Shares it received in the distribution by TRV II to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. After the reported transaction, TRV II directly holds 2,697,829 shares of Common Stock.
The Reporting Person is a partner of TRV GP II, which is the general partner of TRV II. The Reporting Person disclaims beneficial ownership over the 2,697,829 shares held by TRV II, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares.
Third Rock Ventures III, L.P. ("TRV III") directly holds 3,048,780 shares of the Issuer's Common Stock. The Reporting Person is a partner of Third Rock Ventures GP III, L.P., which is the general partner of TRV III. The Reporting Person disclaims beneficial ownership over the shares held by TRV III, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares.
The shares are directly held by the Reporting Person. Includes Shares received in the distributions described in footnote (1) above.
/s/ Cary Pfeffer
2021-09-17